IVERIC bio Net Income

As of the most recent data (March 2023), ISEE shows a net income of $-210M. That compares with $-120M in the prior-year period — down 73.9% year over year. That is below the Healthcare sector average of $16B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ISEE's net income is now $-210M (was $-120M) — a 73.9% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether IVERIC bio is outperforming or lagging.

The Healthcare sector average net income is about $16B. IVERIC bio is at $-210M, which is lower that average. That is roughly 101.3% below the sector mean. Use the comparison chart on this page to see how ISEE stacks up against individual peers as well.

Tracking ISEE's net income over time shows whether IVERIC bio is scaling, shrinking, or reshaping that part of the business. The current reading is $-210M That compares with $-120M in the prior-year period — down 73.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this net income page, Stockcircle has IVERIC bio's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net income (currently $-210M) with ownership activity and broader fundamentals.